Pricing Log in Create free account

Evommune Inc. (EVMN) vs Keros Therapeutics, Inc. (KROS)

Evommune Inc. and Keros Therapeutics, Inc. are both Biotechnology companies. Evommune Inc. and Keros Therapeutics, Inc. are of similar size ($220.1M and $215.2M). Across the 11 metrics below, Keros Therapeutics, Inc. leads on 8 and Evommune Inc. on 3.

Valuation

Metric EVMN KROS Biotechnology median
P/E n/m n/m 8.50
P/S n/m 6.37 9.71
P/B 0.67 0.81 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.13 0.46 0.64
EV/Sales n/m (1.39) 9.21
Earnings yield (213.35%) (34.64%) (33.15%)
Free cash flow yield (39.96%) (22.93%) (25.50%)

Profitability

Metric EVMN KROS Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (141.99%) (17.16%) (56.36%)
Return on assets (62.71%) (15.92%) (48.04%)
Return on invested capital (82.46%) (1,345.30%) 0.00%

Growth

Metric EVMN KROS Biotechnology median
Revenue growth (TTM) — (84.55%) 6.02%
EPS growth (last fiscal year) 75.23% 146.00% 30.26%
Revenue growth, 5-year CAGR — 89.45% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric EVMN KROS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.68 21.96 4.72
Net debt to EBITDA 1.87 (4.16) 0.96

Dividend

Metric EVMN KROS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric EVMN KROS Biotechnology median
Market cap 215.22m 220.08m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack